HemaSphere (Jun 2022)
P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
- R. Nakamura,
- R. Hendricks,
- R. Dokhaei,
- M. Susilo,
- D. Wilson,
- S. Trudel,
- A. Cohen,
- S. J. Harrison,
- A. Krishnan,
- R. Fonseca,
- J. I. Adamkewicz,
- M. Li,
- C. Wong,
- J. Cooper,
- T. Sumiyoshi
Affiliations
- R. Nakamura
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- R. Hendricks
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- R. Dokhaei
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- M. Susilo
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- D. Wilson
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- S. Trudel
- 2 Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
- A. Cohen
- 3 Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA, United States of America
- S. J. Harrison
- 4 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia
- A. Krishnan
- 5 City of Hope, Duarte, CA
- R. Fonseca
- 6 Mayo Clinic in Arizona, Phoenix, AZ, United States of America
- J. I. Adamkewicz
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- M. Li
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- C. Wong
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- J. Cooper
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- T. Sumiyoshi
- 1 Genentech, Inc., South San Francisco, CA, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000846716.90763.d0
- Journal volume & issue
-
Vol. 6
pp. 852 – 853
Abstract
No abstracts available.